German Science Giant Merck KGaA Agrees to Buy Minneapolis Bio-Techne for $11.3 Billion | SpeakBase Times
Level 1 - Absolute Beginner
A big German company called Merck KGaA wants to buy an American company called Bio-Techne. Bio-Techne is in the city of Minneapolis in the United States.
Merck will pay $73 for each share of Bio-Techne. The total price is about $11.3 billion dollars. That is a very large amount of money.
Bio-Techne makes more than 500,000 products for science laboratories. Scientists around the world use these products to study diseases and make new medicines.
The two companies plan to work together and save $140 million every year. They hope to finish the deal by early 2027.
company
a business that makes or sells things
buy
to give money to get something
billion
one thousand million (1,000,000,000)
share
a small piece of a company that people can buy
products
things that a company makes or sells
laboratory
a room or building where scientists work
deal
an agreement between two sides
save
to keep money instead of spending it
Level 2 - Elementary
German science and healthcare company Merck KGaA announced plans to acquire Bio-Techne, a biotechnology firm based in Minneapolis, Minnesota, for $11.3 billion in an all-cash deal.
Merck will pay $73 per share, which is a 36% premium above the average price that Bio-Techne shares traded at over the past month. Bio-Techne shares jumped nearly 23% on the news.
Bio-Techne offers more than 500,000 laboratory products, including ProteinSimple, a tool for studying proteins, and RNAscope, a tool for studying gene expression inside tissue samples. Scientists at universities and pharmaceutical companies use these products every day.
The companies expect the deal to close by early 2027, after they receive permission from regulators in the United States, Europe, and China. Together they plan to save about $140 million each year within three years.
acquire
to buy and take ownership of another company
premium
an extra amount paid above the normal price
all-cash
paid completely with money, not with shares or borrowed debt
biotechnology
the use of living cells and biology to create medical and scientific products
protein
a large molecule in cells that carries out essential biological functions
regulator
a government body that oversees and approves business transactions
synergy
the combined saving or benefit created when two companies work together
shareholder
a person or company that owns shares in a business
Level 3 - Intermediate
Merck KGaA, the German life-science and healthcare conglomerate, has agreed to acquire Minneapolis-based Bio-Techne Corporation for EUR 9.9 billion ($11.3 billion), representing one of the largest biotechnology takeovers of 2026.
The all-cash bid of $73 per share reflects a 36% premium to Bio-Techne's one-month volume-weighted average price (VWAP), a common benchmark used by acquirers to demonstrate value to target shareholders. Bio-Techne stock surged approximately 23% on the announcement, confirming that investors viewed the offer favorably.
Bio-Techne's catalog of more than 500,000 products spans proteomics, genomics, and cell biology, with standout platforms including ProteinSimple, an automated Western blot system, and RNAscope, a spatial gene-expression assay adopted by more than 5,000 laboratories on six continents. The acquisition substantially expands Merck's reach into North American research accounts where Bio-Techne holds leading market share.
Management forecasts EUR 140 million in annual run-rate synergies by year three, sourced mainly from procurement efficiencies and expanded geographic distribution. Completion is subject to antitrust review in the United States, the European Union, and China, with closing expected in late 2026 or early 2027 pending customary regulatory conditions.
conglomerate
a large corporation made up of many different businesses in varied sectors
takeover
the act of one company gaining control of another by purchasing a majority stake
volume-weighted average price
the average trading price of a stock calculated by weighting each price by the volume traded at that level
proteomics
the large-scale study of proteins, their structure, functions, and interactions
spatial gene-expression
a technique that maps where specific genes are active within sections of tissue
run-rate synergy
the projected annualised saving or revenue gain once a business integration is fully complete
procurement
the process of obtaining goods or services needed by a business
antitrust review
a government examination of a merger or acquisition to ensure it does not reduce market competition
Level 4 - Advanced
Merck KGaA's EUR 9.9 billion ($11.3 billion) all-cash acquisition of Bio-Techne Corporation positions the Darmstadt-based conglomerate as a dominant force in the life-science tools sector, a market characterised by stable, high-margin recurring revenues from consumable reagent sales rather than the episodic capital equipment cycles that define medical-device peers.
At $73 per share, the bid implies an enterprise value approximately 12 times Bio-Techne's trailing twelve-month EBITDA, consistent with precedent transactions in the sector and reflecting the acquirer's conviction that Bio-Techne's proprietary proteomics and spatial genomics platforms warrant a structural premium over commodity reagent suppliers. The 36% VWAP premium is calibrated to clear the supermajority threshold required for shareholder approval while staying below the level that typically triggers appraisal-rights litigation.
Bio-Techne's five-vertical portfolio (protein research via ProteinSimple Western blot automation, spatial genomics via RNAscope in-situ hybridisation, cytokine biology, cell viability assays, and contract research services) addresses distinct research workflows, insulating the combined entity against single-modality disruption while opening cross-sell vectors across Merck's North American and Asia-Pacific installed base. Integration risk is mitigated by Bio-Techne's self-contained commercial infrastructure and its highly tenured scientific sales force, which maintains direct relationships with principal investigators at over 3,000 academic institutions.
The EUR 140 million run-rate synergy target, guided for full realisation by year three, is split roughly 60/40 between procurement savings and revenue uplift from geographic white-space penetration, particularly in Mainland China and Southeast Asia where Bio-Techne distribution has historically been thin. Merck has committed to maintaining Bio-Techne's Minneapolis headquarters and retaining key research personnel, a concession designed to preserve innovation optionality and reduce post-merger attrition risk among the scientific workforce that constitutes the core of Bio-Techne's competitive moat.
consumable reagent
a chemical or biological substance used once during an experiment, generating repeat purchase revenue
EBITDA multiple
a valuation ratio comparing enterprise value to earnings before interest, taxes, depreciation, and amortisation
supermajority
a voting threshold higher than a simple majority, typically two-thirds or more, required for major corporate decisions
appraisal-rights litigation
legal proceedings in which dissenting shareholders challenge an acquisition price in court as being too low
in-situ hybridisation
a laboratory technique that detects specific nucleic acid sequences within fixed tissue sections using complementary probes
installed base
the total number of a company's products or instruments currently in active use at customer sites
white-space penetration
expansion into geographic or market segments where a company currently has little or no commercial presence
competitive moat
a durable structural advantage, such as proprietary technology or deep customer relationships, that protects a company from competitors
German Science Giant Merck KGaA Agrees to Buy Minneapolis Bio-Techne for $11.3 Billion
Merck KGaA, the German life-science and healthcare conglomerate, has agreed to acquire Bio-Techne Corporation of Minneapolis in an all-cash deal worth $11.3 billion, paying $73 per share -- a 36% premium to Bio-Techne's recent average trading price. Bio-Techne, whose portfolio includes ProteinSimple and RNAscope platforms used in laboratories worldwide, saw its shares surge approximately 23% on the news. The merger is expected to deliver EUR 140 million in annual synergies by year three, with closing anticipated in late 2026 or early 2027.
By SpeakBase Times Editorial Team
Level 1 - Absolute Beginner
Ready
Reading PassageTap highlighted words for definitions
A big German company called Merck KGaA wants to buy an American company called Bio-Techne. Bio-Techne is in the city of Minneapolis in the United States.
Merck will pay $73 for each share of Bio-Techne. The total price is about $11.3 billion dollars. That is a very large amount of money.
Bio-Techne makes more than 500,000 products for science laboratories. Scientists around the world use these products to study diseases and make new medicines.
The two companies plan to work together and save $140 million every year. They hope to finish the deal by early 2027.
📝
Key Vocabulary
company —a business that makes or sells things
buy —to give money to get something
billion —one thousand million (1,000,000,000)
share —a small piece of a company that people can buy
products —things that a company makes or sells
laboratory —a room or building where scientists work
deal —an agreement between two sides
save —to keep money instead of spending it
Exercises
Multiple Choice
1What is the name of the German company?
2How much will Merck pay for each share?
3Where is Bio-Techne located?
4How many products does Bio-Techne make?
5How much will the two companies save each year?
True or False
6Merck KGaA is a German company.
7Bio-Techne is based in France.
8The total deal is worth $11.3 billion.
9Bio-Techne makes fewer than 1,000 products.
10The deal should be finished by early 2027.
Fill in the Blank
11Merck KGaA will pay ___ for each Bio-Techne share.
12Bio-Techne makes more than ___ science products.
13The two companies hope to save ___ million dollars every year.
